Archives of Obesity and Metabolism (비만대사연구학술지)

The Study of Obesity and Metabolic Syndrome, KAFM (대한가정의학회 비만대사증후군연구회)
권호 표지
DOI QR코드

DOI QR Code

Oral Drugs for Treatment of Dyslipidemia and Cardiovascular Disease Prevention

이상지질혈증 경구용 약제와 심혈관질환 예방효과

  • Lee, Yun-Ah (Department of Family Medicine, College of Medicine, The Catholic University of Korea, St. Vincent's Hospital) ;
  • Rho, JunSeung (Department of Family Medicine, College of Medicine, The Catholic University of Korea, St. Vincent's Hospital) ;
  • Song, Sang-Wook (Department of Family Medicine, College of Medicine, The Catholic University of Korea, St. Vincent's Hospital) ;
  • Jung, Su-Young (Department of Family Medicine, College of Medicine, The Catholic University of Korea, St. Vincent's Hospital) ;
  • Kwon, Ji Young (Department of Family Medicine, College of Medicine, The Catholic University of Korea, St. Vincent's Hospital) ;
  • Kang, Sung-Goo (Department of Family Medicine, College of Medicine, The Catholic University of Korea, St. Vincent's Hospital)
  • 이윤아 (가톨릭대학교 가정의학교실, 성빈센트병원) ;
  • 노준승 (가톨릭대학교 가정의학교실, 성빈센트병원) ;
  • 송상욱 (가톨릭대학교 가정의학교실, 성빈센트병원) ;
  • 정수영 (가톨릭대학교 가정의학교실, 성빈센트병원) ;
  • 권지영 (가톨릭대학교 가정의학교실, 성빈센트병원) ;
  • 강성구 (가톨릭대학교 가정의학교실, 성빈센트병원)
  • Received : 2022.05.09
  • Accepted : 2022.06.16
  • Published : 2022.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

In 1971, Dr. Akira Endo succeeded in isolating a cholesterol synthesis inhibitor, compactin. Later, compactin was renamed mevastatin, meaning that it stops the synthesis of mevalonate, which is considered the first statin. However, mevastatin is not commercially released, whereas lovastatin, developed by Alfred Albert of Merk in 1979, was the first commercially developed statin. After the 4S study, the first largescale clinical trial with statins conducted in Scandinavia showed a dramatic secondary preventive effect against cardiovascular disease, and the effectiveness of statins in patients with dyslipidemia was repeatedly demonstrated. Subsequently, many oral drugs that affect blood lipid concentration; statins and ezetimibe aimed at reducing low-density lipoprotein (LDL)) cholesterol; fibrates and omega 3 formulations aimed at reducing triglycerides were widely developed and used in Korea. In this article, we review the results of clinical studies on representative cardiovascular diseases for four types of oral drugs for dyslipidemia, which are currently the most commonly used in Korea.

Keywords

References

  1. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7. https://doi.org/10.1056/NEJM199511163332001
  2. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-22. https://doi.org/10.1001/jama.279.20.1615
  3. Sever PS, Dahlof B, Poulter NR, et al.; ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58. https://doi.org/10.1016/S0140-6736(03)12948-0
  4. Colhoun HM, Betteridge DJ, Durrington PN, et al. CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96. https://doi.org/10.1016/S0140-6736(04)16895-5
  5. Ridker PM, Danielson E, Fonseca FA, et al. JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207. https://doi.org/10.1056/NEJMoa0807646
  6. Yusuf S, Bosch J, Dagenais G, et al. HOPE-3 Investigators. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med 2016;374:2021-31. https://doi.org/10.1056/NEJMoa1600176
  7. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9. https://doi.org/10.1016/S0140-6736(94)90566-5
  8. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57. https://doi.org/10.1056/NEJM199811053391902
  9. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001;285:1711-8. https://doi.org/10.1001/jama.285.13.1711
  10. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-30. https://doi.org/10.1016/S0140-6736(02)11600-X
  11. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504. Erratum in: N Engl J Med 2006;354:778. https://doi.org/10.1056/NEJMoa040583
  12. Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005;294:2437-45. Erratum in: JAMA 2005;294:3092. https://doi.org/10.1001/jama.294.19.2437
  13. LaRosa JC, Grundy SM, Waters DD, et al.; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35. https://doi.org/10.1056/NEJMoa050461
  14. Patrick JE, Kosoglou T, Stauber KL, et al. Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects. Drug Metab Dispos 2002;30:430-7. https://doi.org/10.1124/dmd.30.4.430
  15. Miura S, Saku K. Ezetimibe, a selective inhibitor of the transport of cholesterol. Intern Med 2008;47:1165-70. https://doi.org/10.2169/internalmedicine.47.1099
  16. Sudhop T, Lutjohann D, Kodal A, et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 2002;106:1943-8. https://doi.org/10.1161/01.CIR.0000034044.95911.DC
  17. Pandor A, Ara RM, Tumur I, et al. Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials. J Intern Med 2009;265:568-80. https://doi.org/10.1111/j.1365-2796.2008.02062.x
  18. Kosoglou T, Meyer I, Veltri EP, et al. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin. Br J Clin Pharmacol 2002;54:309-19. https://doi.org/10.1046/j.1365-2125.2002.01633.x
  19. Kastelein JJ, Akdim F, Stroes ES, et al.; ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008;358:1431-43. Erratum in: N Engl J Med 2008;358:1977. https://doi.org/10.1056/NEJMoa0800742
  20. Rossebo AB, Pedersen TR, Boman K, et al. SEAS Investigators. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008;359:1343-56. https://doi.org/10.1056/NEJMoa0804602
  21. Fleg JL, Mete M, Howard BV, et al. Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. J Am Coll Cardiol 2008;52:2198-205. https://doi.org/10.1016/j.jacc.2008.10.031
  22. Baigent C, Landray MJ, Reith C, et al.; SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011;377:2181-92. https://doi.org/10.1016/S0140-6736(11)60739-3
  23. Cannon CP, Blazing MA, Giugliano RP, et al.; IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015;372:2387-97. https://doi.org/10.1056/NEJMoa1410489
  24. Ouchi Y, Sasaki J, Arai H, et al. Ezetimibe lipid-lowering trial on prevention of atherosclerotic cardiovascular disease in 75 or older (EWTOPIA 75): a randomized, controlled trial. Circulation 2019;140:992-1003. https://doi.org/10.1161/circulationaha.118.039415
  25. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998;98:2088-93. https://doi.org/10.1161/01.CIR.98.19.2088
  26. Staels B, Vu-Dac N, Kosykh VA, et al. Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. J Clin Invest 1995;95:705-12. https://doi.org/10.1172/JCI117717
  27. Lalloyer F, Staels B. Fibrates, glitazones, and peroxisome proliferator-activated receptors. Arterioscler Thromb Vasc Biol 2010;30:894-9. https://doi.org/10.1161/ATVBAHA.108.179689
  28. Caslake MJ, Packard CJ, Gaw A, et al. Fenofibrate and LDL metabolic heterogeneity in hypercholesterolemia. Arterioscler Thromb 1993;13:702-11. https://doi.org/10.1161/01.atv.13.5.702
  29. Mann CJ, Yen FT, Grant AM, Bihain BE. Mechanism of plasma cholesteryl ester transfer in hypertriglyceridemia. J Clin Invest 1991;88:2059-66. https://doi.org/10.1172/JCI115535
  30. Vu-Dac N, Schoonjans K, Kosykh V, et al. Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. J Clin Invest 1995;96:741-50. https://doi.org/10.1172/JCI118118
  31. Keech A, Simes RJ, Barter P, et al. FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-61. Erratum in: Lancet 2006;368:1420. Erratum in: Lancet 2006;368:1415. https://doi.org/10.1016/S0140-6736(05)67667-2
  32. ACCORD Study Group, Ginsberg HN, Elam MB, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-74. Erratum in: N Engl J Med 2010;362:1748. https://doi.org/10.1056/NEJMoa1001282
  33. Shahidi F, Ambigaipalan P. Omega-3 polyunsaturated fatty acids and their health benefits. Annu Rev Food Sci Technol 2018;9:345-81. https://doi.org/10.1146/annurev-food-111317-095850
  34. Shahidi F, Miraliakbari H. Omega-3 (n-3) fatty acids in health and disease: part 1--cardiovascular disease and cancer. J Med Food 2004;7:387-401. https://doi.org/10.1089/jmf.2004.7.387
  35. Harris WS. n-3 fatty acids and serum lipoproteins: human studies. Am J Clin Nutr 1997;65(5 Suppl):1645S-54S. https://doi.org/10.1093/ajcn/65.5.1645S
  36. Balk EM, Lichtenstein AH, Chung M, Kupelnick B, Chew P, Lau J. Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review. Atherosclerosis 2006;189:19-30. https://doi.org/10.1016/j.atherosclerosis.2006.02.012
  37. Skulas-Ray AC, Wilson PWF, Harris WS, et al. Omega-3 fatty acids for the management of hypertriglyceridemia: a science advisory from the American Heart Association. Circulation 2019;140:e673-91.
  38. Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007;369:1090-8. Erratum in: Lancet 2007;370:220. https://doi.org/10.1016/S0140-6736(07)60527-3
  39. Manson JE, Cook NR, Lee IM, et al. Marine n-3 fatty acids and prevention of cardiovascular disease and cancer. N Engl J Med 2019;380:23-32. https://doi.org/10.1056/NEJMoa1811403
  40. ASCEND Study Collaborative Group, Bowman L, Mafham M, et al. Effects of n-3 fatty acid supplements in diabetes mellitus. N Engl J Med 2018;379:1540-50. https://doi.org/10.1056/NEJMoa1804989
  41. Nicholls SJ, Lincoff AM, Garcia M, et al. Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial. JAMA 2020;324:2268-80. https://doi.org/10.1001/jama.2020.22258
  42. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med 2019;380:11-22. https://doi.org/10.1056/NEJMoa1812792
  43. Authors/Task Force Members; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Atherosclerosis 2019;290:140-205. Erratum in: Atherosclerosis 2020;292:160-2. Erratum in: Atherosclerosis 2020;294:80-2. https://doi.org/10.1016/j.atherosclerosis.2019.08.014